{
    "clinical_study": {
        "@rank": "120867", 
        "arm_group": [
            {
                "arm_group_label": "Arginine Stimulation Testing", 
                "arm_group_type": "Experimental", 
                "description": "Establish the methodology for glucose enhanced arginine stimulation testing (AST)."
            }, 
            {
                "arm_group_label": "PET Imaging", 
                "arm_group_type": "Experimental", 
                "description": "Determine if pancreatic PET-determined binding measures of 18F-AV-133 differ in up to 60 subjects determined to be at one of four stages of the natural history of Type 2 Diabetes: Healthy Overweight/obese Volunteers (HOV), Subjects with Pre-diabetes (PD), Early Type 2 Diabetes mellitus (E-T2DM) and Late Type 2 Diabetes mellitus (L-T2DM)"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate 18F-AV-133 imaging of the pancreas in patients with early type 2 diabetes, late\n      type 2 diabetes, subjects with pre-diabetes and in healthy overweight/obese control\n      subjects. These subjects will also be evaluated for beta-cell function as measured by the\n      insulin and C-peptide response to a challenge with intravenous arginine under basal and\n      glucose enhanced conditions."
        }, 
        "brief_title": "Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and/or female subjects of non-childbearing potential between the ages of 30 and\n             65 years inclusive.\n\n          -  Able to tolerate PET, PET/CT and MR imaging\n\n          -  Estimated creatinine clearance >= 60mL/min\n\n          -  Informed consent documents signed and dated by subject\n\n          -  Subjects must be willing and able to comply with all scheduled visits, treatments\n             laboratory tests, scans and other study procedures.\n\n          -  In addition, subjects must meet classification requirements for one of the following\n\n               1. Healthy Overweight\n\n               2. Pre-diabetes\n\n               3. E-T2DM\n\n               4. L-T2DM\n\n          -  Subjects with other chronic medical conditions (besides diabetes) that are well\n             controlled and stable on medication are acceptable for inclusion in this study.\n\n        Exclusion Criteria:\n\n          -  Subjects who are affiliated with or relatives of staff members of either the site or\n             Pfizer directly involved in the conduct of the trial.\n\n          -  Conditions which in the opinion of the study investigator may interfere with the\n             subject's ability to participate in the study\n\n          -  History of allergic reaction to drug/contrast agent or history of drug/alcohol abuse\n\n          -  Subjects who have received investigational medications within the last 30 days or a\n             radiopharmaceutical in the past 7 days.\n\n          -  Pregnant or nursing females; females of childbearing potential."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "68", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01710371", 
            "org_study_id": "A9001458"
        }, 
        "intervention": [
            {
                "arm_group_label": "PET Imaging", 
                "description": "296 MBq (8 mCi)", 
                "intervention_name": "18F-AV-133", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arginine Stimulation Testing", 
                    "PET Imaging"
                ], 
                "intervention_name": "10% Arginine Hydrochloride-R-Gene 10", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 1, 2013", 
        "location": {
            "contact": {
                "last_name": "New Haven 24 Hour Phoneline", 
                "phone": "203-401-0300"
            }, 
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06511"
                }, 
                "name": "Research Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Quantitative PET Imaging of Pancreatic Beta-Cell Mass in Healthy Overweight/Obese Subjects, Subjects With Prediabetes, and Type 2 Diabetes Patients With 18F-FP-DTBZ (18F-AV-133)", 
        "overall_contact": {
            "email": "clinicaloperations@avidrp.com", 
            "last_name": "Avid Clinical Operations", 
            "phone": "215-298-0700"
        }, 
        "overall_official": {
            "affiliation": "Avid Radiopharmaceuticals", 
            "last_name": "Chief Medical Officer", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Optimal PET-determined mean pancreatic Binding Potential of 18F-AV-133", 
                "safety_issue": "No", 
                "time_frame": "PET visit 1"
            }, 
            {
                "measure": "Optimal PET-determined mean pancreatic Standardized Uptake Value (SUV) of 18F-AV-133", 
                "safety_issue": "No", 
                "time_frame": "PET visit 1"
            }, 
            {
                "measure": "Optimal PET-determined mean pancreatic Volume of Distribution (VT) of 18F-AV-133", 
                "safety_issue": "No", 
                "time_frame": "PET visit 1"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01710371"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Avid Radiopharmaceuticals", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Avid Radiopharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}